2028 Biosimilars Chemotherapy 
Big Molecule Watch
DECEMBER 16, 2024
UDENYCA , the only biosimilar to Amgens NEULASTA in the United States, is administered the day after chemotherapy treatment to decrease the incidence of infection by febrile neutropenia. The post Intas Expands Cancer Therapy Biosimilar Portfolio appeared first on Big Molecule Watch.
pharmaphorum
AUGUST 2, 2022
The trial involved cancer immunotherapy-naïve patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) patients who were getting treatment with Tecentriq second-line after earlier platinum-based chemotherapy failed. Results from a trial in first-line NSCLC are due in early 2023.
Expert insights. Personalized for you.
45 
Let's personalize your content